Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats

References

• Bernhardt R, Urlacher VB. (2014). Cytochromes P450 as promising catalysts for biotechnological application: chances and limitations. Appl Microbiol Biotechnol 98:6185–203.
   PubMed Web of Science ®Google Scholar
• Chen W, Li J, Sun Z, et al. (2018). Comparative pharmacokinetics of six coumarins in normal and breast cancer bone-metastatic mice after oral administration of Wenshen Zhuanggu formula. J Ethnopharmacol 224:36–44.
   PubMed Web of Science ®Google Scholar
• Crespi CL, Miller VP. (1997). The R144C change in the CYP2C9* 2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7:203–10.
   PubMedGoogle Scholar
• Daniel WA, Haduch A, Syrek M, et al. (2006). Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment. Eur Neuropsychopharmacol 16:580–7.
   PubMed Web of Science ®Google Scholar
• Doggrell SA. (2004). Inhibition of cardiac cytochrome P450: a new approach to cardiac ischaemia and reperfusion damage. Expert Opin Ther Targets 8:491–3.
   PubMed Web of Science ®Google Scholar
• Du R, Xue J, Wang HB, et al. (2011). Osthol ameliorates fat milk-induced fatty liver in mice by regulation of hepatic sterol regulatory element-binding protein-1c/2-mediated target gene expression. Eur J Pharmacol 666:183–8.
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Martinez C, Ladero JM, et al. (2006). Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 10:29–40.
   PubMed Web of Science ®Google Scholar
• Gotoh O. (1992). Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83–90.
   PubMed Web of Science ®Google Scholar
• He L, Li C, Liu X, et al. (2017). Comparative study on the interaction between 3 CYP2C9 allelic isoforms and benzbromarone by using LC–MS/MS method. J Chromatogr B Analyt Technol Biomed Life Sci 1070:97–103.
   PubMed Web of Science ®Google Scholar
• He SM, Zhou ZW, Li XT, et al. (2011). Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. Curr Med Chem 18:667–713.
   PubMed Web of Science ®Google Scholar
• Hiratsuka M. (2016). Genetic polymorphisms and in vitro functional characterization of CYP2C8, CYP2C9, and CYP2C19 allelic variants. Biol Pharm Bull 39:1748–59.
   PubMed Web of Science ®Google Scholar
• Huang LH, Zhong YM, Xiong XH, et al. (2016). The disposition of oxymatrine in the vascularly perfused rat intestine-liver preparation and its metabolism in rat liver microsomes. J Pharm Sci 105:897–903.
   PubMed Web of Science ®Google Scholar
• Jarząb A, Grabarska A, Skalicka-Woźniak K, et al. (2017). Pharmacological features of osthole. Postepy Hig Med Dosw 71:411–421.
   Web of Science ®Google Scholar
• Jiang G, Liu J, Ren B, et al. (2016). Anti-tumor effects of osthole on ovarian cancer cells in vitro. J Ethnopharmacol 193:368–76.
   PubMed Web of Science ®Google Scholar
• Karaźniewicz-Łada M, Łuczak M, Główka F. (2009). Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes. Xenobiotica 39:476–85.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim DH, Byeon JY, et al. (2017). Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Arch Pharm Res 40:382–90.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Bauer S, Meineke I, et al. (2002). Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin and glucose response in healthy volunteers. Pharmacogenetics 12:101–9.
   PubMedGoogle Scholar
• Liang HJ, Suk FM, Wang CK, et al. (2009). Osthole, a potential antidiabetic agent alleviates hyperglycemia in db/db mice. Chem Biol Interact 181:309–15.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, et al. (1951). Protein measurement with the Folin phenol reagent. Biol Chem 193:265–75.
   Web of Science ®Google Scholar
• McGraw J, Waller M. (2012). Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 8:371–82.
   PubMed Web of Science ®Google Scholar
• Pan Z, Fang Z, Lu W, et al. (2015). Osthole, a coumadin analog from Cnidium monnieri (L.) Cusson, stimulates corticosterone secretion by increasing steroidogenic enzyme expression in mouse Y1 adrenocortical tumor cells. J Ethnopharmacol 175:456–62.
   PubMed Web of Science ®Google Scholar
• Polonikov A, Bykanova M, Ponomarenko I, et al. (2017). The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population. Clin Exp Hypertens 39:306–11.
   PubMed Web of Science ®Google Scholar
• Qiu F, Zhang R, Sun J, et al. (2008). Inhibitory effects of seven components of Danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos 7:1308–14.
   Google Scholar
• Sachse-Seeboth C, Pfeil1 J, Sehrt D, et al. (2009). Interindividual variation in the pharmacokinetics of Δ9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther 85:273–6.
   PubMed Web of Science ®Google Scholar
• Sausville LN, Gangadhariah MH, Chiusa M, et al. (2018). The cytochrome P450 slow metabolizers CYP2C9*2 and CYP2C9*3 directly regulate tumorigenesis via reduced epoxyeicosatrienoic acid production. Cancer Res 78:4865–77.
   PubMed Web of Science ®Google Scholar
• Sun F, Xie ML, Xue J, et al. (2010). Osthol regulates hepatic PPAR alpha-mediated lipogenic gene expression in alcoholic fatty liver murine. Phytomedicine 17:669–73.
   PubMed Web of Science ®Google Scholar
• Takanashi K, Tainaka H, Kobayashi K, et al. (2000). CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10:95–104.
   PubMedGoogle Scholar
• Wang B, Zheng X, Liu J, et al. (2018). Osthole inhibits pancreatic cancer progression by directly exerting negative effects on cancer cells and attenuating tumor-infiltrating M2 macrophages. J Pharmacol Sci 137:290–8.
   PubMed Web of Science ®Google Scholar
• Xu R, Liu Z, Hou J, et al. (2018). Osthole improves collagen-induced arthritis in a rat model through inhibiting inflammation and cellular stress. Cell Mol Biol Lett 23:19.
   PubMed Web of Science ®Google Scholar
• Yang KH, Choi YH, Lee U, et al. (2009). Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism. J Pharm Pharmacol 61:47–54.
   PubMed Web of Science ®Google Scholar
• Yang L, Ge W, Yu F, et al. (2010). Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement – a systematic review and meta analysis. Thromb Res 125:159–66.
   PubMed Web of Science ®Google Scholar
• Zhang L, Jiang G, Yao F, et al. (2012). Growth inhibition and apoptosis induced by osthole, a natural coumarin, in hepatocellular carcinoma. PLoS One 7:37–65.
   Google Scholar
• Zhang J, Xue J, Wang H, et al. (2011). Osthole improves alcohol-induced fatty liver in mice by reduction of hepatic oxidative stress. Phytother Res 25:638–43.
   PubMed Web of Science ®Google Scholar
• Zhao X, Xue J, Wang XL, et al. (2014). Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats. Int Immunopharmacol 22:176–81.
   PubMed Web of Science ®Google Scholar
• Zhu X, Lee DY, Shin WG. (2007). Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. Biopharm Drug Dispos 28:125–33.
   PubMed Web of Science ®Google Scholar
• Zoungas S, Patel A, Chalmers J, et al. (2010). Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410–8.
   PubMed Web of Science ®Google Scholar